KR20190075120A - Bmp 강화제 - Google Patents

Bmp 강화제 Download PDF

Info

Publication number
KR20190075120A
KR20190075120A KR1020197016038A KR20197016038A KR20190075120A KR 20190075120 A KR20190075120 A KR 20190075120A KR 1020197016038 A KR1020197016038 A KR 1020197016038A KR 20197016038 A KR20197016038 A KR 20197016038A KR 20190075120 A KR20190075120 A KR 20190075120A
Authority
KR
South Korea
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
disease
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020197016038A
Other languages
English (en)
Korean (ko)
Inventor
지안 딩
마리-헬렌 라라우피
데보라 로스만
닉 새비지
사오원 왕
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20190075120A publication Critical patent/KR20190075120A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020197016038A 2016-11-10 2017-11-08 Bmp 강화제 Withdrawn KR20190075120A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662420535P 2016-11-10 2016-11-10
US62/420,535 2016-11-10
PCT/IB2017/056991 WO2018087677A1 (en) 2016-11-10 2017-11-08 Bmp potentiators

Publications (1)

Publication Number Publication Date
KR20190075120A true KR20190075120A (ko) 2019-06-28

Family

ID=60569967

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197016038A Withdrawn KR20190075120A (ko) 2016-11-10 2017-11-08 Bmp 강화제

Country Status (15)

Country Link
US (2) US10259827B2 (cg-RX-API-DMAC7.html)
EP (1) EP3538531A1 (cg-RX-API-DMAC7.html)
JP (1) JP2019534302A (cg-RX-API-DMAC7.html)
KR (1) KR20190075120A (cg-RX-API-DMAC7.html)
CN (1) CN109923118A (cg-RX-API-DMAC7.html)
AR (1) AR110163A1 (cg-RX-API-DMAC7.html)
AU (1) AU2017357719A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019009404A2 (cg-RX-API-DMAC7.html)
CA (1) CA3043575A1 (cg-RX-API-DMAC7.html)
EA (1) EA201991141A1 (cg-RX-API-DMAC7.html)
MX (1) MX2019005504A (cg-RX-API-DMAC7.html)
RU (1) RU2019117548A (cg-RX-API-DMAC7.html)
TW (1) TW201821076A (cg-RX-API-DMAC7.html)
UY (1) UY37477A (cg-RX-API-DMAC7.html)
WO (1) WO2018087677A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119751235A (zh) * 2019-01-23 2025-04-04 约翰霍普金斯大学 非免疫抑制性fk506类似物及其用途
WO2026059989A1 (en) * 2024-09-10 2026-03-19 Montara Therapeutics, Inc. Peripheral blockers for central nervous system-selective drug activity
WO2026060005A1 (en) * 2024-09-10 2026-03-19 Montara Therapeutics, Inc. Macrocyclic blockers for use in the reduction of peripheral side effects due to everolimus therapy

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0346427B1 (en) 1987-12-09 1995-03-29 FISONS plc Macrocyclic compounds
EP0378318A1 (en) 1989-01-11 1990-07-18 Merck & Co. Inc. Process for synthesis of FK-506 and tricarbonyl intermediates
GR1001225B (el) 1989-09-14 1993-06-30 Fisons Plc Νέαι μακροκυκλικαί ενώσεις και νέα μέ?οδος χρήσεως τους.
GB9014136D0 (en) * 1990-06-25 1990-08-15 Fujisawa Pharmaceutical Co Tricyclo compounds,a process for their production and a pharmaceutical composition containing the same
DE4028664A1 (de) * 1990-09-10 1992-03-12 Sandoz Ag Heteroatome enthaltende, tricyclische verbindungen, verfahren zu ihrer herstellung und ihre verwendung
DE4028676A1 (de) * 1990-09-10 1992-03-12 Sandoz Ag Heteroatome enthaltende, tricyclische verbindungen, verfahren zu ihrer herstellung und ihre verwendung
DE4028677A1 (de) * 1990-09-10 1992-03-12 Sandoz Ag Heteroatome enthaltende, tricyclische verbindungen, verfahren zu ihrer herstellung und ihre verwendung
DE4028675A1 (de) * 1990-09-10 1992-03-12 Sandoz Ag Heteroatome enthaltende, tricyclische verbindungen, verfahren zu ihrer herstellung und ihre verwendung
DE4028666A1 (de) * 1990-09-10 1992-03-12 Sandoz Ag Heteroatome enthaltende, tricyclische verbindungen, verfahren zu ihrer herstellung und ihre verwendung
CA2071332A1 (en) * 1991-06-25 1992-12-26 Laszlo R. Treiber C-21 hydroxylated fk-506 antagonist
GB9202196D0 (en) 1992-02-01 1992-03-18 Fisons Plc Method of treatment
US5284877A (en) * 1992-06-12 1994-02-08 Merck & Co., Inc. Alkyl and alkenyl macrolides having immunosuppressive activity
GB9218027D0 (en) 1992-08-25 1992-10-14 Fisons Plc Novel method of treatment
GB9218597D0 (en) 1992-08-25 1992-10-14 Fisons Plc Novel method of treatment
US7109317B1 (en) * 1998-11-06 2006-09-19 President And Fellows Of Harvard College FK506-based regulation of biological events
WO2000058318A1 (en) 1999-03-31 2000-10-05 Abbott Laboratories Phosphate containing macrocyclic immunomodulators
US6569867B2 (en) 1999-10-01 2003-05-27 Kosan Biosciences, Inc. Polyketide derivatives
EP1282626A2 (en) 2000-05-17 2003-02-12 Kosan Biosciences, Inc. Polyketide derivatives
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
AU2006206525A1 (en) * 2005-01-20 2006-07-27 Array Biopharma Nc. Macrocyclic analogs for the treatment of immunoregulatory disorders and respiratory diseases
WO2012047762A2 (en) 2010-10-08 2012-04-12 Amplyx Pharmaceuticals, Inc. Antifungal agents
WO2015106283A1 (en) 2014-01-13 2015-07-16 Amplyx Pharmaceuticals, Inc. Antifungal compounds

Also Published As

Publication number Publication date
CA3043575A1 (en) 2018-05-17
BR112019009404A2 (pt) 2019-07-30
US20180127436A1 (en) 2018-05-10
AU2017357719A1 (en) 2019-05-16
MX2019005504A (es) 2019-08-12
AR110163A1 (es) 2019-02-27
TW201821076A (zh) 2018-06-16
RU2019117548A (ru) 2020-12-10
JP2019534302A (ja) 2019-11-28
CN109923118A (zh) 2019-06-21
WO2018087677A1 (en) 2018-05-17
UY37477A (es) 2018-06-29
US10259827B2 (en) 2019-04-16
US20190194227A1 (en) 2019-06-27
EA201991141A1 (ru) 2019-10-31
EP3538531A1 (en) 2019-09-18

Similar Documents

Publication Publication Date Title
AU2018348241B2 (en) Solid forms of a compound for modulating kinases
CN108434149B (zh) 针对Rb阳性异常细胞增殖的HSPC节制性治疗
JP6537527B2 (ja) Jak及びpi3k阻害剤併用によるb細胞悪性腫瘍の処置
EP3692015B1 (en) Novel glutamine antagonists and uses thereof
TWI603977B (zh) 作為激酶抑制劑之化合物及組合物
EP3004108B1 (en) Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease
EP3004112B1 (en) Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease
JP2018527398A (ja) ヘテロ環式化合物およびそれらの使用
RS57723B1 (sr) Jak1 inhibitori za lečenje mijelodisplastičnog sindroma
JP2024521791A (ja) 脳又はcnsへの癌転移を治療するためのegfrデグレーダー
MX2012009894A (es) Inhibidores dimericos de iap.
KR101800140B1 (ko) 벤조티아졸론 화합물
US10259827B2 (en) BMP potentiators
EP4104861A1 (en) Therapeutic agent for tauopathies
WO2025101571A1 (en) Tetrahydroisoquinoline heterobifunctional bcl-x l degraders
AU2016359438A1 (en) Diamino pyridine derivatives
JP7227398B2 (ja) ベンズイミダゾール誘導体及びその使用
CA3079029C (en) Solid forms of a compound for modulating kinases
HK40082418A (en) Pyridopyrimidinone derivatives and their use as aryl hydrocarbon receptor modulators
HK1222792B (en) Hspc-sparing treatments for rb-positive abnormal cellular proliferation
HK1260112B (en) Hspc-sparing treatments for rb-positive abnormal cellular proliferation
HK1260112A1 (en) Hspc-sparing treatments for rb-positive abnormal cellular proliferation
HK1242324A1 (en) New substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190604

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination